20.500.12556/DiRROS-12422 Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1 by the USA Food and Drug Administration non-small cell lung carcinoma drug therapy KEYNOTE-024 trial pemrolizumab treatment nedrobnocelični karcinom pljuč terapija z zdravili raziskava KEYNOTE-024 pemrolizumab zdravljenje true false true Elsevier Angleški jezik Ni določen © 2019 THE AUTHORS Neznano 2020-09-21 11:57:10 2020-09-21 11:57:10 2022-08-18 03:37:20 0000-00-00 00:00:00 2019 0 Velika Britanija 0 Nasl. z nasl. zaslona; Soavtorica iz Slovenije: T. Cufer; Opis vira z dne 15. 1. 2020; str. 1686-1688 iss. 11 Vol. 30 Nov. 2019 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.2 1569-8041 10.1093/annonc/mdz295 2048615281 3151892 RAZ_Mountzios_Giannis_i2019.pdf RAZ_Mountzios_Giannis_i2019.pdf 1 0E9697A221FB531E45F7409FE050F7AE 1bdad3a66871089a7fe89fd345d65ffafe674986494eef32f26e030469f62480 8d8fc2b0-17b6-11ed-b6b8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=17307 https://academic.oup.com/annonc/article-abstract/30/11/1686/5559466?redirectedFrom=fulltext 1 https://dirros.openscience.si/Dokument.php?lang=slv&id=14984 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0